FAK Inhibitor 14: Selective FAK Pathway Blockade in Cancer Research

Executive Summary: FAK Inhibitor 14 (benzene-1,2,4,5-tetraamine tetrahydrochloride; SKU B7400) is a small molecule inhibitor designed for the targeted suppression of focal adhesion kinase (FAK) activity, a process central to cell migration and tumor progression (product info). Its efficacy is validated in cholesterol-resistant ovarian cancer models, where it impedes FAK/Src/COL5A1 signaling and epithelial-mesenchymal transition (EMT) (He et al., 2024). The compound displays high solubility in water (≥11.5 mg/mL) and DMSO (≥2.6 mg/mL), but is insoluble in ethanol. Quality is confirmed at >98% purity by HPLC and NMR, and it is shipped under blue ice for integrity. FAK Inhibitor 14 is exclusively for research and should be stored desiccated at room temperature (APExBIO).

Biological Rationale

Focal adhesion kinase (FAK) orchestrates key steps in cell adhesion, motility, and survival. Its aberrant activation is strongly implicated in cancer progression, metastasis, and drug resistance. In ovarian cancer, the FAK/Src/COL5A1 axis has emerged as a critical mediator of cellular responses to chronic high cholesterol, driving epithelial-mesenchymal transition (EMT) and tumorigenesis (He et al., 2024). Targeting FAK with selective inhibitors such as FAK Inhibitor 14 enables researchers to dissect these pathways and assess the impact on cancer cell behavior under defined experimental conditions. This approach is particularly valuable in models displaying resistance to conventional therapies or altered lipid metabolism.

Mechanism of Action of FAK Inhibitor 14

FAK Inhibitor 14 acts as a competitive inhibitor at the ATP-binding site of FAK, thereby blocking its autophosphorylation and downstream signal propagation. By preventing FAK activation, the compound disrupts Src-mediated phosphorylation events and suppresses the upregulation of target genes such as COL5A1, which are essential for EMT and tumor invasion. In cholesterol-resistant ovarian cancer models, this disruption halts PARP1/FAK/COL5A1 signaling and impedes the acquisition of migratory and invasive phenotypes (He et al., 2024). The molecular weight of FAK Inhibitor 14 is 284.01, and its structure allows for high aqueous solubility, facilitating in vitro applications across various cell-based systems (APExBIO).

Evidence & Benchmarks

• FAK Inhibitor 14 (B7400) achieves >98% purity as verified by HPLC and NMR, supporting reproducibility in cell-based assays (product info).
• In cholesterol-resistant ovarian cancer cells, FAK Inhibitor 14 blocks FAK/Src/COL5A1 signaling, resulting in reduced EMT and tumorigenic potential (He et al., 2024).
• Suppression of FAK activity by FAK Inhibitor 14 leads to significant downregulation of COL5A1 expression in vitro and in vivo, correlating with decreased tumor progression (He et al., 2024).
• The compound is highly soluble in water (≥11.5 mg/mL) and DMSO (≥2.6 mg/mL with ultrasonic treatment), but insoluble in ethanol, enabling diverse protocol designs (APExBIO).
• Storage at room temperature in a desiccated environment preserves compound integrity, but solutions are recommended for short-term use only (APExBIO).

Applications, Limits & Misconceptions

FAK Inhibitor 14 is used primarily in cancer biology research to dissect FAK-driven signaling pathways, especially in contexts of cell migration inhibition and tumor metastasis. The compound is indispensable for studying cholesterol-induced resistance mechanisms, as demonstrated in recent ovarian cancer models. For more detailed experimental workflows, readers can consult 'Applied Workflows Using FAK Inhibitor 14 in Cancer Research', which emphasizes hands-on protocol optimization—this article extends those guides by providing updated mechanistic and benchmark data.

Other resources, such as 'Applied Use of FAK Inhibitor 14 in Cancer Biology Research' and 'Applied Use of FAK Inhibitor 14 in Cancer Biology Research', focus on practical troubleshooting and reproducibility. Here, we further clarify validated molecular targets and storage parameters, addressing misconceptions about ethanol solubility and long-term solution stability.

Common Pitfalls or Misconceptions

• FAK Inhibitor 14 is not soluble in ethanol; attempts to dissolve the solid in ethanol will fail and may compromise experimental reproducibility (APExBIO).
• The compound is intended exclusively for scientific research; it is not approved for diagnostic or therapeutic use in humans or animals.
• Long-term storage of prepared solutions can result in loss of potency; freshly prepared solutions are recommended for critical assays.
• FAK Inhibitor 14 selectively targets FAK and does not broadly inhibit unrelated kinases; off-target effects should not be assumed without empirical validation.
• Incorrect storage outside of desiccated, room temperature conditions may lead to degradation or reduced activity.

Workflow Integration & Parameters

Integrating FAK Inhibitor 14 into cancer biology workflows requires careful attention to solubility, dosing, and storage controls. The compound's high purity and defined solubility profile enable its use in a range of in vitro assays investigating FAK signaling, EMT, and cell migration. For precise protocol guidance, studies recommend the following parameters:

Protocol Parameters

• Solubilization: Dissolve in water (≥11.5 mg/mL) or DMSO (≥2.6 mg/mL with ultrasonic treatment) for stock preparation.
• Working solution preparation: Prepare fresh solutions immediately prior to use; avoid storage beyond short-term to maintain potency.
• Cell treatment: Apply FAK Inhibitor 14 to cell cultures at concentrations matching literature precedent (e.g., as used in cholesterol-resistant ovarian cancer cell studies), adjusting for cell type and assay.
• Compound storage: Store solid compound desiccated at room temperature; do not refrigerate or freeze unless specified by protocol.
• Shipping: Receive under blue ice conditions to preserve chemical integrity during transit.

For a stepwise workflow and troubleshooting, see Applied Workflows Using FAK Inhibitor 14 in Cancer Research, which this article complements by presenting updated mechanistic evidence and validated protocol parameters.

Conclusion & Outlook

The validated inhibition of FAK/Src/COL5A1 signaling by FAK Inhibitor 14 establishes its utility as a research tool for dissecting the molecular basis of cell adhesion, migration, and tumor progression in cancer models. In ovarian cancer with cholesterol-driven resistance, the compound has been shown to suppress EMT and tumorigenic capacity (He et al., 2024). Future applications will likely refine its use in mechanistic studies and preclinical model systems, providing insights for next-generation cancer therapeutics. All claims and recommendations are grounded in the cited literature and product documentation, ensuring high translational value for experimental design.